Personalized medicine in diabetes mellitus: current opportunities and future prospects
JW Kleinberger, TI Pollin - Annals of the New York Academy of …, 2015 - Wiley Online Library
Diabetes mellitus affects approximately 382 million individuals worldwide and is a leading
cause of morbidity and mortality. Over 40 and nearly 80 genetic loci influencing susceptibility …
cause of morbidity and mortality. Over 40 and nearly 80 genetic loci influencing susceptibility …
Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals
F Lavernia, SE Adkins, JH Shubrook - Postgraduate medicine, 2015 - Taylor & Francis
The management of type 2 diabetes mellitus (T2DM) by primary care physicians (PCPs) has
become increasingly complex due to limitations on consultation time, an increasing array of …
become increasingly complex due to limitations on consultation time, an increasing array of …
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial
S Matthaei, K Bowering, K Rohwedder, A Grohl… - Diabetes …, 2015 - Am Diabetes Assoc
OBJECTIVE To evaluate the efficacy and safety of dapagliflozin in patients with type 2
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study
Objectives: The study objective was to evaluate the effects of sitagliptin in patients with type
2 diabetes (T2D) and heart failure (HF). Background: There is uncertainty in the literature …
2 diabetes (T2D) and heart failure (HF). Background: There is uncertainty in the literature …
Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS
H Akimoto, A Negishi, S Oshima… - American Journal of …, 2020 - journals.sagepub.com
Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and
the risk of AD may depend on the antidiabetic drug administered. We compared the risk of …
the risk of AD may depend on the antidiabetic drug administered. We compared the risk of …
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes
RA DeFronzo, CF Burant, P Fleck… - The Journal of …, 2012 - academic.oup.com
Context: Optimal management of type 2 diabetes remains an elusive goal. Combination
therapy addressing the core defects of impaired insulin secretion and insulin resistance …
therapy addressing the core defects of impaired insulin secretion and insulin resistance …
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
Objective To determine if the use of sitagliptin in newly treated patients with type 2 diabetes
is associated with any changes in clinical outcomes. Design Retrospective population based …
is associated with any changes in clinical outcomes. Design Retrospective population based …
Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics
NM Doliba, W Qin, H Najafi, C Liu… - American Journal …, 2012 - journals.physiology.org
It was reported previously that isolated human islets from individuals with type 2 diabetes
mellitus (T2DM) show reduced glucose-stimulated insulin release. To assess the possibility …
mellitus (T2DM) show reduced glucose-stimulated insulin release. To assess the possibility …
Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation …
Objectives To compare the patterns of 18 physical and mental health comorbidities between
people with recently diagnosed type 2 diabetes (T2D) and people without diabetes and how …
people with recently diagnosed type 2 diabetes (T2D) and people without diabetes and how …
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes
T Stargardt, L Gonder-Frederick, KJ Krobot… - Health and quality of life …, 2009 - Springer
Background To explore the concept of the Minimum Clinically Important Difference (MID) of
the Worry Scale of the Hypoglycaemia Fear Survey (HFS-II) and to quantify the clinical …
the Worry Scale of the Hypoglycaemia Fear Survey (HFS-II) and to quantify the clinical …